Contraception

Nextstellis (drospirenone; estetrol) now is approved as a combined oral contraceptive for birth control.

This video interview features Rachael Phelps, MD, Medical Director at Planned Parenthood of Central and Western New York, and of the Rochester LARC Initiative; and Amber Truehart, MD, Assistant Professor of Obstetrics and Gynecology, Section of Family Planning and Contraceptive Research at the University of Chicago.

A prospective study to assess the effects of an oral contraceptive containing estetrol and drospirenone on ovarian function found treatment achieved complete ovulation inhibition.

The pandemic has forced us to get more creative in managing patients’ needs, especially when it comes to contraception

This video interview features Rachael Phelps, MD, Medical Director at Planned Parenthood of Central and Western New York, and of the Rochester LARC Initiative; and Amber Truehart, MD, Assistant Professor of Obstetrics and Gynecology, Section of Family Planning and Contraceptive Research at the University of Chicago.

In this episode, Dr. Rachel Phelps of the Rochester LARC Initiative sits down with Dr. Amber Trueheart of the University of Chicago Department of Obstetrics and Gynecology.

Limited changes occur in endocrine markers with the combined oral contraceptive Nextstellis (Mayne Pharma), according to a prospective study presented at the virtual annual meeting of the International Society for the Study of Women's Sexual Health (ISSWSH) in March.

Since 2012, when South Carolina's Medicaid program became the first state Medicaid program to separate payment for the immediate postpartum placement of long-acting reversible contraception (LARC) from global maternity payment, a significantly greater number of mothers are using LARC, especially among adolescents.

When it comes to willingness to switch contraception method, a team of researchers has looked into whether method type, satisfaction with use, and confidence in correct use were independently associated with switching intentions.

The mechanism of action (MOA) of emergency contraceptive pills (ECPs) is frequently mischaracterized among the general public, according to authors of a recent study published in the journal Contraception.

Three experts in maternal-fetal medicine hosted the Womxn’s Health Collaborative Symposium: Crucial conversations for careers in MFM during the Society for Maternal Fetal Medicine’s (SMFM) 41st Annual Pregnancy Meeting on Monday.

Initiation of more effective contraception occurred more often among patients who were seen by a volunteer reproductive health educator during routine visits at a resident obstetrics and gynecology clinic, according to a study published in Maternal and Child Health Journal.

In response to the coronavirus disease 2019 pandemic, many U.S. family planning providers have started offering telemedicine services.

The study in the Brazilian Journal of Nursing also found that the IUD complications were the same as those commonly cited in the literature.

The ever-use of an intrauterine device (IUD) reduces the risk of ovarian cancer by an average of 30%, according to a rigorous meta-analysis in the Journal of Obstetrics and Gynaecology.

Less than half of ob/gyns offer their patients the two most effective forms of emergency contraception -- ulipristal acetate and the copper intrauterine device (IUD) -- according to a national survey.

Neither the levonorgestrel-releasing intrauterine system (LNG-IUS) nor the copper intrauterine device (IUD) impact the incidence of cellular atypia, but do interfere with the microbiota over time, according to liquid-based cervical cytology and microbiological analyses.

A prospective interventional hospital-based study from India has found that a postpartum intrauterine copper device (PPIUCD) is an efficacious method to reduce the unmet need of contraception.

A summary of key findings from the National Center for Health Statistics (NCHS) recent data brief, No.388, October 2020.

“Telehealth visits serve to ensure patient-centered, shared decision-making counseling, as well as allowing the provider to confirm that the patients are good candidates with no contraindications for their method of choice,” Eve Espey, MD, MPH, said.

Although hypertension is a modifiable risk factor for cardiovascular disease (CVD), certain hormonal contraceptives increase the risk of stroke and myocardial infarction in women with the disorder.

Oral contraceptive pills are a popular choice for many; providers should understand the options to guide patients effectively.

An overwhelming 84% of young women in the United States who reported using contraception chose their method based on factors other than provider recommendation, according to a survey.

Yesterday, on August 11, 2020, the FDA posted the first spreadsheet of adverse event reports.

Transgender and nonbinary people face disproportionate rates of stigma and discrimination in seeking healthcare—and may encounter additional unique barriers in attaining gynecologic and reproductive care.